Literature DB >> 29708135

Meet the new boss: lung cancer staging.

Abbie Begnaud1, Robert A Kratzke2.   

Abstract

Entities:  

Year:  2018        PMID： 29708135      PMCID： PMC5906223          DOI： 10.21037/jtd.2018.03.89

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  15 in total

1.  Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.

Authors:  Gary M Strauss; James E Herndon; Michael A Maddaus; David W Johnstone; Elizabeth A Johnson; David H Harpole; Heidi H Gillenwater; Dorothy M Watson; David J Sugarbaker; Richard L Schilsky; Everett E Vokes; Mark R Green
Journal:  J Clin Oncol       Date:  2008-09-22       Impact factor: 44.544

2.  Duke fraud case highlights financial risks for universities.

Authors:  Alison McCook
Journal:  Science       Date:  2016-09-02       Impact factor: 47.728

3.  A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer.

Authors:  Anil Potti; Sayan Mukherjee; Rebecca Petersen; Holly K Dressman; Andrea Bild; Jason Koontz; Robert Kratzke; Mark A Watson; Michael Kelley; Geoffrey S Ginsburg; Mike West; David H Harpole; Joseph R Nevins
Journal:  N Engl J Med       Date:  2006-08-10       Impact factor: 91.245

4.  Lung cancer survival in the United States by race and stage (2001-2009): Findings from the CONCORD-2 study.

Authors:  Thomas B Richards; S Jane Henley; Mary C Puckett; Hannah K Weir; Bin Huang; Thomas C Tucker; Claudia Allemani
Journal:  Cancer       Date:  2017-12-15       Impact factor: 6.860

Review 5.  A new international staging system for lung cancer.

Authors:  C F Mountain
Journal:  Chest       Date:  1986-04       Impact factor: 9.410

6.  Poor correspondence between clinical and pathologic staging in stage 1 non-small cell lung cancer: results from CALGB 9761, a prospective trial.

Authors:  Jonathan D'Cunha; James E Herndon; Debra L Herzan; G Alexander Patterson; Leslie J Kohman; David H Harpole; Kemp H Kernstine; Jeffrey A Kern; Mark R Green; Michael A Maddaus; Robert A Kratzke
Journal:  Lung Cancer       Date:  2005-01-04       Impact factor: 5.705

Review 7.  Comprehensive evaluation of published gene expression prognostic signatures for biomarker-based lung cancer clinical studies.

Authors:  H Tang; S Wang; G Xiao; J Schiller; V Papadimitrakopoulou; J Minna; I I Wistuba; Y Xie
Journal:  Ann Oncol       Date:  2017-04-01       Impact factor: 32.976

8.  Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy.

Authors:  Frances A Shepherd; Benjamin Lacas; Gwénaël Le Teuff; Pierre Hainaut; Pasi A Jänne; Jean-Pierre Pignon; Thierry Le Chevalier; Lesley Seymour; Jean-Yves Douillard; Stephen Graziano; Elizabeth Brambilla; Robert Pirker; Martin Filipits; Robert Kratzke; Jean-Charles Soria; Ming-Sound Tsao
Journal:  J Clin Oncol       Date:  2017-04-28       Impact factor: 44.544

Review 9.  Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non-Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update.

Authors:  Mark G Kris; Laurie E Gaspar; Jamie E Chaft; Erin B Kennedy; Christopher G Azzoli; Peter M Ellis; Steven H Lin; Harvey I Pass; Rahul Seth; Frances A Shepherd; David R Spigel; John R Strawn; Yee C Ung; Michael Weyant
Journal:  J Clin Oncol       Date:  2017-04-24       Impact factor: 44.544

10.  Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial.

Authors:  Kathy S Albain; R Suzanne Swann; Valerie W Rusch; Andrew T Turrisi; Frances A Shepherd; Colum Smith; Yuhchyau Chen; Robert B Livingston; Richard H Feins; David R Gandara; Willard A Fry; Gail Darling; David H Johnson; Mark R Green; Robert C Miller; Joanne Ley; Willliam T Sause; James D Cox
Journal:  Lancet       Date:  2009-07-24       Impact factor: 79.321
View more
  1 in total

1.  Invited letter to the editor on the editorial on "Clinical staging of NSCLC: current evidence and implications for adjuvant chemotherapy".

Authors:  David Jonathan Heineman; Johannes Marlene Daniels; Wilhelmina Hendrika Schreurs
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.